Literature DB >> 17386969

Effects of botulinum toxin A on the contractile function of dog prostate.

Alex Tong Long Lin1, An Hang Yang, Kuang-Kuo Chen.   

Abstract

OBJECTIVES: To study effects of botulinum toxin A (BoNT/A) on prostate contractile function in dogs.
METHODS: One hundred units (N=6) or 200 units (N=5) BoNT/A was injected into dog prostate. Sham control group (N=7) received normal saline injections. Before and 1 mo after injection, prostate urethral pressure response to electrostimulation and intravenous (IV) norepinephrine was measured. Contractile responses of prostate strips were tested in tissue bath. Structural changes were evaluated with conventional histology and smoothelin immunohistochemistry.
RESULTS: Injection of normal saline and 100 units BoNT/A did not significantly change prostate urethral pressure response to IV norepinephrine and electrostimulation. However, injection of 200 units BoNT/A significantly reduced prostate urethral pressure response to IV norepinephrine and electrostimulation. Contractile responses of prostate strips to potassium chloride, electrostimulation, and phenylephrine did not differ between sham control and 100U groups. In the 200U group, however, all responses were less than those of sham controls. Control and BoNT/A groups exhibited nitric oxide-related relaxation in prostate strips precontracted by phenylephrine. Injection of 100 units BoNT/A induced mild atrophy of prostate gland; injection of 200 units BoNT/A induced more pronounced atrophic changes in prostate gland and vacuoles formation in smooth muscle cells of stromal tissue.
CONCLUSIONS: Injecting BoNT/A into dog prostate reduces contractile function while maintaining relaxation response of the prostate. These effects make BoNT/A a viable option in managing prostate-related symptoms. However, large, randomized clinical studies to determine long-term effects and safety of BoNT/A application in human prostates are required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17386969     DOI: 10.1016/j.eururo.2007.03.002

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

Review 1.  Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery.

Authors:  Michael B Chancellor
Journal:  Int Urol Nephrol       Date:  2009-07-02       Impact factor: 2.370

2.  [Intraprostatic injection therapy in patients with benign prostatic syndrome].

Authors:  T Bschleipfer; T Bach; C Gratzke; S Madersbacher; M Oelke
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

Review 3.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

4.  Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates.

Authors:  Ali Hamidi Madani; Ahmad Enshaei; Abtin Heidarzadeh; Gholamreza Mokhtari; Alireza Farzan; Mani Mohiti Asli; Samaneh Esmaeili
Journal:  World J Urol       Date:  2012-03-13       Impact factor: 4.226

Review 5.  New intraprostatic injectables and prostatic urethral lift for male LUTS.

Authors:  Giuseppe Magistro; Christian G Stief; Christian Gratzke
Journal:  Nat Rev Urol       Date:  2015-07-21       Impact factor: 14.432

Review 6.  [Botulinum toxin in the treatment of benign prostatic hyperplasia : an overview].

Authors:  S Boy; C Seif; P M Braun; K-P Jünemann
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

Review 7.  Hitting below the belt (bladder): botulinum treatment of urethral and prostate disorders.

Authors:  H Henry Lai; Christopher P Smith
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

Review 8.  Current and potential urological applications of botulinum toxin A.

Authors:  Yuan-Hong Jiang; Chun-Hou Liao; Hann-Chorng Kuo
Journal:  Nat Rev Urol       Date:  2015-08-11       Impact factor: 14.432

9.  Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.

Authors:  João Silva; Rui Pinto; Tiago Carvalho; Francisco Botelho; Pedro Silva; Rui Oliveira; Carlos Silva; Francisco Cruz; Paulo Dinis
Journal:  BMC Urol       Date:  2009-08-15       Impact factor: 2.264

10.  Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement.

Authors:  Cristian P Ilie; Michael B Chancellor; Yao-Chi Chuang; Mischianu Dan
Journal:  J Med Life       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.